Compare FGBI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FGBI | MCRB |
|---|---|---|
| Founded | 1934 | 2010 |
| Country | United States | United States |
| Employees | 339 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.1M | 139.7M |
| IPO Year | N/A | 2015 |
| Metric | FGBI | MCRB |
|---|---|---|
| Price | $8.26 | $9.33 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $14.33 |
| AVG Volume (30 Days) | 6.3K | ★ 43.8K |
| Earning Date | 05-11-2026 | 03-12-2026 |
| Dividend Yield | ★ 0.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | $567.70 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $14.28 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.31 | $0.36 |
| 52 Week High | $10.55 | $29.98 |
| Indicator | FGBI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 47.84 |
| Support Level | $8.18 | $7.55 |
| Resistance Level | $8.33 | $9.53 |
| Average True Range (ATR) | 0.28 | 0.62 |
| MACD | -0.04 | 0.21 |
| Stochastic Oscillator | 18.93 | 87.05 |
First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.